PATENT APPLICATION



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Alison M. Bendele, et al.

Serial No.:

10/621,784

Group Art Unit No.:

1649

Filed:

July 16, 2003

Examiner: Christina M. Borgeest

For:

USE OF IL-1 INHIBITORS FOR TREATING

IL-1 MEDIATED DISEASES

Docket No.:

A-398-US-CNT3

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Under the guidelines of 37 C.F.R. 1.97, applicants submit a copy of each of the references listed on the attached supplemental PTO-1449 (Modified) form for consideration by the Examiner.

Applicants make no determination of relevancy with respect to the references submitted herewith and request the Examiner to make an independent determination of relevance and/or materiality of the references.

Applicants, by the undersigned attorney/agent, certifiy that each item contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than 30 days, pursuant to 37 C.F.R. 1.704(d), prior to the filing of this information disclosure statement.

Applicant(s) request(s) consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any

EXPRESS MAIL CERTIFICATE

"Express Mail" label number:

EL 732552287 US

Date of Deposit: February 3, 2009

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313;1450.

Karen Podgorny

Printed Name

overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,

Mary K. Hehman

Attorney for Applicants
Registration No.:

Phone: (805) 447-5632 Date: February 3, 2009

Please send all future correspondence to:

U.S. Patent Operations/ MKH Dept. 4300, M/S 28-2-C AMGEN INC. One Amgen Center Drive Thousand Oaks, California 91320-1799



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Alison M. Bendele, et al.

Serial No.:

10/621,784

Group Art Unit No.:

1649

Filed:

July 16, 2003

Examiner: Christina M. Borgeest

For:

USE OF IL-1 INHIBITORS FOR TREATING

IL-1 MEDIATED DISEASES

Docket No.:

A-398-US-CNT3

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Under the guidelines of 37 C.F.R. 1.97, applicants submit a copy of each of the references listed on the attached supplemental PTO-1449 (Modified) form for consideration by the Examiner.

Applicants make no determination of relevancy with respect to the references submitted herewith and request the Examiner to make an independent determination of relevance and/or materiality of the references.

Applicants, by the undersigned attorney/agent, certifiy that each item contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than 30 days, pursuant to 37 C.F.R. 1.704(d), prior to the filing of this information disclosure statement.

Applicant(s) request(s) consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any

EXPRESS MAIL CERTIFICATE

"Express Mail" label number:

EL 732552287 US

Date of Deposit: February 3, 2009

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313,1450.

> Karen Podgorny Printed Name

overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,

Mary K/Hehman

Attorney for Applicants
Registration No.: 39

Phone: (805) 447-5632

Date: February 3, 2009

Please send all future correspondence to:

U.S. Patent Operations/ MKH
Dept. 4300, M/S 28-2-C
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799